Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	88673
Country	China

Received	2023-10-04 13:27
Peer-Review Started	2023-10-04 13:29
To Make the First Decision
Return for Revision	2023-12-18 08:41
Revised	2023-12-29 15:53
Second Decision	2024-02-18 07:08
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-02-18 07:54
Articles in Press	2024-02-18 07:54
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-02-05 16:50
Typeset the Manuscript	2024-03-04 09:29
Publish the Manuscript Online	2024-04-11 02:23

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Kun-Peng Ma, Jin-Xin Fu, Feng Duan and Mao-Qiang Wang
ORCID	Author(s) ORCID Number Feng Duan http://orcid.org/0000-0001-8432-590X Mao-Qiang Wang http://orcid.org/0000-0002-0299-5289
Funding Agency and Grant Number
Corresponding Author	Mao-Qiang Wang, MD, PhD, Deputy Director, Department of Interventional Radiology, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, No. 28 Fuxin Road, Haidian District, Beijing 100853, China. wangmaoqiang301@163.com
Key Words	Transarterial chemoembolization; Efficacy; Lenvatinib; Programmed cell death protein-1 inhibitors; Unresectable hepatocellular carcinoma
Core Tip	Transarterial chemoembolization/lenvatinib/programmed cell death protein-1 combined treatment was well tolerated with encouraging efficacy in unresectable hepatocellular carcinoma patients. The patients in Barcelona Clinic Liver Cancer Classification (BCLC) B, with early neutrophil-to-lymphocyte ratio (NLR) response (decrease) and early alpha fetoprotein (AFP) response (decrease > 20%) might achieve better clinical outcomes in the triple therapy. It is advisable that BCLC stage, NLR, and AFP should be considered within clinical decision-making in order to obtain better prognosis.
Publish Date	2024-04-11 02:23
Citation	Ma KP, Fu JX, Duan F, Wang MQ. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(4): 1236-1247
URL	https://www.wjgnet.com/1948-5204/full/v16/i4/1236.htm
DOI	https://dx.doi.org/10.4251/wjgo.v16.i4.1236

Full Article (PDF)	WJGO-16-1236-with-cover.pdf
Manuscript File	88673_Auto_Edited-Webster J-ZH-YJP.docx
Answering Reviewers	88673-Answering reviewers.pdf
Audio Core Tip	88673-Audio core tip.mp3
Biostatistics Review Certificate	88673-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	88673-Conflict-of-interest statement.pdf
Copyright License Agreement	88673-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	88673-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	88673-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	88673-Language certificate.pdf
Supplementary Material	88673-Supplementary material.pdf
Peer-review Report	88673-Peer-review(s).pdf
Scientific Editor Work List	88673-Scientific editor work list.pdf
CrossCheck Report	88673-CrossCheck report.pdf